Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZX flat after Vital announcement
Markets

NZX flat after Vital announcement

The NZX was flat, but property stocks declined more than 1%.

Economic hedges help ANZ NZ lift annual profit
Finance

Economic hedges help ANZ NZ lift annual profit

ANZ NZ styles its full-year results as solid as net-interest margin nudges higher.

PaySauce shares rise as it eyes Australia
Markets

PaySauce shares rise as it eyes Australia

Customer numbers for micro and rural payroll firm increased 9% for six months to Sept 30.

Vital Healthcare taking property portfolio management in-house
Markets

Vital Healthcare taking property portfolio management in-house

UPDATED: 'Relatively welcome' – NZSA on Vital's $220m plan.